Study Group: Physicians who Implant Cypher Stents
Council Members in this Study Group: 89
This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.
Contact Gerson Lehrman Group to survey or consult with members of this Study Group
Leading institutions connect with members of this Study Group through GLG
Leading Experts in this Study Group
- Charles O'Shaughnessy
Director of Interventional Cardiology
NORTH OHIO HEART CENTER, INC
Charles O'Shaughnessy, MD, is the Director of Interventional Cardiology at North Ohio Heart Center, Ohio. Dr. O'Shaughnessy's clinical interests are in interventional cardiology including balloon angioplasty, laser directional atherectomy, stent placement,...
Rohit AroraProfessor of Medicine
Finch University of Health Science-Chicago Medical SchoolRohit Arora, MD, FACC, FAHA, FASCI, FACP, is Professor of Medicine and Professor of Physiology and Biophysics at Chicago Medical School. He is also the Chairman of Cardiology and Associate Chairman of Medicine in the Department of Medicine. Previously,...
- Paul Gurbel
Director of Cardiovascular Research
Sinai Hospital of Baltimore, Inc.Paul Gurbel, MD, is Director of Cardiovascular Research at the Center for Thrombosis Research at Sinai Hospital of Baltimore. Dr. Gurbel has authored over 100 peer-reviewed papers related primarily to coronary thrombosis and interventional cardiology....
Giuseppe Biondi-ZoccaiAssistant Professor of Cardiology
University of TurinGiuseppe Biondi-Zoccai, MD, is an Assistant Professor of Cardiology and an Attending Physician in Interventional Cardiology at the University of Turin, Italy, since October 2006. Dr. Biondi-Zoccai has expertise in interventional cardiology, peripheral...
- Ramin Ebrahimi
Director of Cardiac Catheterization Lab
Wadsworth VA Medical CenterRamin Ebrahimi, MD, is Associate Clinical Professor at the University of California in Los Angeles. He is also Director of the Cardiac Catheterization Laboratory and Assistant Director of Nuclear Cardiology at the Wadsworth VA Medical Center. Dr. Ebrahimi’s...
GLG NewsSM Analyses by this Study Group's Leading Experts(?)
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
-
December 15, 2008
Analysis by: Goran Olivecrona, Consulting Cardiologist,Retrospective studies should be viewed with caution. Most retrospective studies which may contain a bias in the prescribed treatment should be anlysed with matched propencity score. To confirm the results a randomized trial would essentially be needed.
-
December 5, 2008
Generic Heart Drugs as Good as Brand-Name Counterparts | www.washingtonpost.com
Generic drugs are cheaper equivalent of brand-name (aka proprietary) drugs which become available after a specific drug patent expires. There is ongoing debate whether generic drugs are as safe and as effective as their brand-name counterparts. Recent evidence from a comprehensive review published in the authoritative Journal of the American Medical Association suggests that generic drugs for heart disease are as safe and as effective as the corresponding proprietary drugs. Thus, given their lower cost, generic drugs may progressively reduce the market share of brand-name drugs, especially whenever a proprietary drug is very expensive or its market position depends only on monopoly rather than effective branding and marketing.
-
May 30, 2008
Metabolic Syndrome Not Useful in Predicting Cardiovascular Risk | www.medpagetoday.com
Metabolic syndrome is a cluster of individual characteristics that has been preliminarily associated with adverse events such as heart attack and stroke If proved an independent cause of cardiovascular disease, metabolic. syndrome could become another feasible target of pharmacologic primary prevention, eg of rimonabant, a novel drug from Sanofi-Aventis that is also under investigation for the treatment/prevention of obesity. However, recent data published in a leading journal, the Lancet, cast a shadow of doubt on independent causal role of the metabolic syndrome, suggesting that its unfavorable impact on patient outlook is largely explained by other risk factors such as increased blood pressure, increased blood lipids, and inflammation.
-
Preventing Bariatric Surgery Deaths
January 25, 2008
Pinning Down Mortality Rates After Bariatric Surgery | www.medscape.com
Bariatric surgery is a major operative procedure that caries significant morbidity and mortality risks due to the comorbid diseases seen in this patient population. This procedure is increasing in frequency as more patients are willing to have it and more surgeons are becoming proficient. The mortality rate is ~ 1 % at 1 year and 6% at 5 years which is greater than the population at large.
-
November 23, 2007
Study Shows Weight-Loss Drug Rimonabant is Associated with Severe Adverse Psychiatric Events | pharmalive.com
The pooled analysis of Rimonabant trials point to a significant increase in psychiatric disorders. These studies also point to significant improvements in markers of cardiovascular risk. Risks versus benefits must be considered before the final decision is made on this class of medications.
Members in this Study Group include these company types:
- Academic Medical Center/Hospital or Clinic
- Office Based Private Practice or Clinic
- Non-Academic Community Hospital or Clinic
- Other Freestanding Healthcare Facility
- Government/Military Hospital or Clinic
Members in this Study Group often have these job titles:
- Physician - Attending Physician
- Physician - Director
- Physician - Division Head
- Director
- President
- Owner